Business Context and Reporting Period
This Form 8-K, dated January 28, 1998, reports the fourth quarter and full-year 1997 earnings for E. I. du Pont de Nemours and Company (DuPont). The filing highlights the company's transition into the 21st century through strategic acquisitions in chemicals, energy, and life sciences, marking the fourth consecutive year of record underlying earnings.
Key Financial Metrics
| Metric | Q4 1997 | Q4 1996 | Full Year 1997 | Full Year 1996 |
|---|---|---|---|---|
| Sales | $11.33 billion | $11.41 billion | $45.08 billion | $43.81 billion |
| Net Income (Reported) | $262 million | $858 million | $2.41 billion | $3.64 billion |
| Net Income (Underlying) | $946 million | $858 million | $4.09 billion | $3.74 billion |
| Basic EPS (Reported) | $0.23 | $0.76 | $2.12 | $3.23 |
| Basic EPS (Underlying) | $0.84 | $0.76 | $3.61 | $3.31 |
| Total Debt (Net of Cash) | Year-end 1997: $11.1 billion |
Note: Underlying figures exclude nonrecurring charges totaling $0.61 per share for the quarter and $1.49 per share for the year, primarily related to in-process research and development write-offs from acquisitions.
Material Changes vs. Prior Period
- Earnings Growth: Underlying earnings per share increased 11% for the quarter and 9% for the full year compared to 1996, despite a 7% negative impact from currency fluctuations.
- Debt Increase: Net debt rose by $3.1 billion to $11.1 billion, driven by $5.5 billion in strategic investments, partially offset by internally generated cash flow.
- Segment Performance:
- Petroleum (Conoco): Achieved record earnings of $1.1 billion (up 19%) and increased reserves by 38%.
- Chemicals & Specialties: Sales volumes rose 7% globally; after-tax income reached a record $3.4 billion.
- Life Sciences: Reported earnings declined 23% to $607 million, largely due to the absence of a $186 million favorable allocation from the DuPont Merck joint venture in the prior year.
Guidance, Outlook, and Risks
Management anticipates a challenging first half of 1998 due to the economic situation in Asia and weaker oil prices. However, the company expects to deliver another record year driven by volume growth in Chemicals and Specialties, favorable raw material pricing, and reduced currency impact. Strategic initiatives include streamlining administrative work to improve productivity.
Risks and Contingencies:
- Currency: A stronger U.S. dollar negatively impacted sales prices outside the United States.
- Acquisition Integration: Significant charges were incurred for in-process R&D related to acquisitions of Pioneer Hi-Bred, Protein Technologies International, and ICI businesses.
- Divestitures: Pending sales of graphic arts films and printing businesses resulted in asset write-downs.
Investor Verification Checklist
- Verify the sustainability of the 9% underlying earnings growth given the 7% currency headwind.
- Confirm the integration progress and future cash flow potential of the $7 billion in announced acquisitions.
- Monitor the impact of weaker oil prices on the Petroleum segment's 1998 performance.
- Assess the timeline and financial impact of the pending divestitures in the Diversified Businesses segment.
- Review the $11.1 billion net debt position relative to future capital expenditure needs.